IBA began its existence in 1986 as a spin-off of the Cyclotron Research Center of Louvain-la-Neuve (UCL).

While initially active in medical imaging, IBA quickly recognized the need to diversify. So, the company turned its attention to radiotherapy and developed cyclotrons able to treat numerous forms of cancer with a degree of precision and efficacy not possible before. The Company merged CIS Bio International in 2008. The product range of CIS Bio includes Y-90, Re-186, Er-169 for RSO and Y-90 chloride which is used with Ibritumomab Tiuxetan (produced by Bayer), Sm-153 for Pain Palliation, I-131 capsules and solutions, Ga-67 sitrat, cold kits and Tc-99m Generators.

http://www.iba-worldwide.com

 
©2018 RADMED A.Ş.   Yasal Uyarı

[ ana sayfa ]  [ site haritası ]  [ İletişim ]  [ Arama ]  [ English ]